*** all the covid vaccine on the market are still on trial ***
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04516746 |
Recruitment Status : Active, not recruitingFirst Posted : August 18, 2020Last Update Posted : April 13, 2021 |
Sponsor:AstraZenecaCollaborator:Iqvia Pty LtdInformation provided by (Responsible Party):AstraZeneca
Study DescriptionGo to Brief Summary:The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19SARS-CoV-2 | Biological: AZD1222Biological: Placebo | Phase 3 |
Detailed Description:The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.Study DesignGo to
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32459 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Participants are assigned to one of two or more groups in parallel for the duration of the study. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Double Blind: two or more parties are unaware of the intervention assignment. |
Primary Purpose: | Treatment |
Official Title: | A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |
Actual Study Start Date : | August 28, 2020 |
Actual Primary Completion Date : | March 5, 2021 |
Estimated Study Completion Date : | February 14, 2023 |
Arms and InterventionsGo to
Arm | Intervention/treatment |
---|---|
Experimental: AZD1222Approximately 20,000 participants randomized to the AZD1222 arm | Biological: AZD1222AZD12222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein. |
Placebo Comparator: PlaceboApproximately 10,000 participants randomized to the saline placebo arm | Biological: PlaceboCommercially available 0.9% (n/V) saline for injection. |
Outcome MeasuresGo to
Primary Outcome Measures :
- The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19 [ Time Frame: 1 year ]A binary response, whereby a participant is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case.
- The safety and tolerability of 2 IM doses of AZD1222 compared to saline placebo [ Time Frame: a: 28 days post each dose of study Intervention. / b: from Day 1 post-treatment through Day 730. ]
- Incidence of adverse events.
- Incidence of serious adverse events, medically attended adverse events, and adverse events of special interest.
- The reactogenicity of 2 IM doses of AZD1222 compared to saline placebo (Substudy only) [ Time Frame: 7 days post each dose of study intervention. ]Incidence of local and systemic solicited adverse events.
Secondary Outcome Measures :
- The efficacy of 2 IM doses of AZD1222 compared tosaline placebo for the prevention of SARS-CoV-2 infection [ Time Frame: 1 year ]The incidence of the first post-treatment response (negative at baseline to positive post treatment with study intervention) for SARS-CoV-2 Nucleocapsid antibodies occurring greater than or equal to 15 days post second dose of study intervention.
- The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of symptomatic COVID-19 using CDC criteria [ Time Frame: 1 year ]The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness for a participant occurring at or after 15 days post second dose of study intervention using criteria from the CDC.
- The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of University of Oxford defined symptomatic COVID-19 [ Time Frame: 1 year ]The incidence of the first case of SARS-CoV-2 RT-PCR positive symptomatic illness occurring ≥ 15 days post second dose of study intervention using University of Oxford defined symptom criteria.
- The efficacy of 2 IM doses of AZD12222 compared to saline placebo for the prevention of severe or critical symptomatic COVID-19. [ Time Frame: 1 year ]The incidence of SARS-CoV-RT-PCR-positive severe or critical symptomatic illness occurring 15 days or more post second dose of study intervention. The incidence of SARS-CoV-2 RT-PCR positive severe or critical symptomatic illness occurring post first dose of study intervention
- The efficacy of 2 IM doses of AZD1222 compared to saline placebo for the prevention of COVID-19-related Emergency Department visits [ Time Frame: 1 year ]The incidence of COVID-19-related Emergency Department visits occurring ≥ 15 days post second dose of study intervention
- Antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only) [ Time Frame: 28 days post each dose ]Post-treatment GMTs and GMFRs in SARS-CoV-2 S, RBD antibodies (MSD serology assay); The proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to the S, RBD antigens of AZD1222 (MSD serology assay)
- Anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or saline placebo (Substudy and Illness Visits only) [ Time Frame: 28 days post each dose ]Post-treatment GMTs and GMFRs in SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay); Proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to AZD1222 as measured by SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay)
- The efficacy of 2 IM doses of AZD1222 compared to saline placebo in the prevention of COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection [ Time Frame: 1 year ]The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring ≥ 15 days post second dose of study intervention regardless of evidence of prior SARS-CoV-2 infection
- The efficacy of AZD1222 compared to saline placebo for the prevention of COVID-19 following the first dose [ Time Frame: 1 year ]The incidence of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring post first dose of study intervention
https://clinicaltrials.gov/ct2/show/NCT04516746
Related posts:
Views: 0